Description

Brigatinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

ATC Classification

Code
Title
Category
brigatinib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XE Protein kinase inhibitors